CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
16.41
0.24%
Market Trading Hours* (UTC) Opens on Friday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.09
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Neogenomics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 16.45
Open* 16.48
1-Year Change* 25.32%
Day's Range* 15.54 - 16.48
52 wk Range 10.51-21.22
Average Volume (10 days) 801.55K
Average Volume (3 months) 21.97M
Market Cap 1.98B
P/E Ratio -100.00K
Shares Outstanding 127.47M
Revenue 574.80M
EPS -0.77
Dividend (Yield %) N/A
Beta 1.12
Next Earnings Date Feb 21, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 22, 2024 16.41 -0.22 -1.32% 16.63 16.78 15.52
Feb 21, 2024 16.45 0.38 2.36% 16.07 16.45 14.98
Feb 20, 2024 14.67 0.70 5.01% 13.97 14.95 13.97
Feb 16, 2024 14.31 -0.31 -2.12% 14.62 14.84 14.29
Feb 15, 2024 14.84 -0.13 -0.87% 14.97 15.15 14.73
Feb 14, 2024 14.85 0.30 2.06% 14.55 14.89 14.31
Feb 13, 2024 14.25 -0.07 -0.49% 14.32 14.54 14.14
Feb 12, 2024 15.12 0.78 5.44% 14.34 15.28 14.29
Feb 9, 2024 14.32 -0.15 -1.04% 14.47 14.87 14.29
Feb 8, 2024 14.45 0.56 4.03% 13.89 14.75 13.74
Feb 7, 2024 14.01 -0.29 -2.03% 14.30 14.33 13.98
Feb 6, 2024 14.44 0.37 2.63% 14.07 14.62 14.02
Feb 5, 2024 14.12 -0.23 -1.60% 14.35 14.53 14.12
Feb 2, 2024 14.63 0.21 1.46% 14.42 14.64 14.19
Feb 1, 2024 14.75 -0.22 -1.47% 14.97 15.17 14.68
Jan 31, 2024 14.80 -0.54 -3.52% 15.34 15.63 14.75
Jan 30, 2024 15.43 -0.73 -4.52% 16.16 16.22 15.33
Jan 29, 2024 16.35 0.88 5.69% 15.47 16.36 15.35
Jan 26, 2024 15.57 -0.40 -2.50% 15.97 16.01 15.53
Jan 25, 2024 15.83 -0.15 -0.94% 15.98 16.30 15.79

NeoGenomics Events

Time (UTC) Country Event
Monday, May 6, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Neogenomics Inc Earnings Release
Q1 2024 Neogenomics Inc Earnings Release

Forecast

-

Previous

-
Friday, May 24, 2024

Time (UTC)

14:00

Country

US

Event

Neogenomics Inc Annual Shareholders Meeting
Neogenomics Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 509.728 484.329 444.448 408.83 276.741
Revenue 509.728 484.329 444.448 408.83 276.741
Cost of Revenue, Total 321.832 297.269 258.555 211.994 149.476
Gross Profit 187.896 187.06 185.893 196.836 127.265
Total Operating Expense 667.351 603.083 459.84 396.842 266.701
Selling/General/Admin. Expenses, Total 277.906 229.799 169.366 165.418 111.924
Research & Development 28.485 21.18 8.029 8.487 3.001
Unusual Expense (Income) 4.516 15.683 3.473 1.018 2.3
Operating Income -157.623 -118.754 -15.392 11.988 10.04
Interest Income (Expense), Net Non-Operating -1.506 104.178 -10.525 -3.713 -6.23
Other, Net -0.213 -0.499 11.861 -4.63 0.014
Net Income Before Taxes -159.342 -15.075 -14.056 3.645 3.824
Net Income After Taxes -144.25 -8.347 4.172 8.006 2.64
Net Income Before Extra. Items -144.25 -8.347 4.172 8.006 2.64
Net Income -144.25 -8.347 4.172 8.006 2.64
Total Adjustments to Net Income 0 0 3.448
Income Available to Common Excl. Extra. Items -144.25 -8.347 4.172 8.006 6.088
Income Available to Common Incl. Extra. Items -144.25 -8.347 4.172 8.006 6.088
Diluted Net Income -144.25 -8.347 4.172 8.006 6.088
Diluted Weighted Average Shares 124.217 119.962 111.794 103.615 91.568
Diluted EPS Excluding Extraordinary Items -1.16127 -0.06958 0.03732 0.07727 0.06649
Diluted Normalized EPS -1.07899 0.08258 0.01375 0.13741 0.08383
Total Extraordinary Items
Depreciation / Amortization 34.612 39.152 20.417 9.925
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 146.917 137.22 138.705 128.782 125.072
Revenue 146.917 137.22 138.705 128.782 125.072
Cost of Revenue, Total 87.026 82.406 81.88 79.889 81.126
Gross Profit 59.891 54.814 56.825 48.893 43.946
Total Operating Expense 176.811 172.293 165.088 168.292 164.774
Selling/General/Admin. Expenses, Total 75.279 73.878 68.282 77.257 70.133
Research & Development 7.502 7.395 6.675 7.312 8.626
Depreciation / Amortization 3.93 3.93 3.735 3.637 3.637
Unusual Expense (Income) 3.074 4.684 4.516 0.197 1.252
Operating Income -29.894 -35.073 -26.383 -39.51 -39.702
Interest Income (Expense), Net Non-Operating 2.524 1.467 0.86 -0.139 -0.926
Other, Net 0.73 -0.114 -0.001 0.025 -0.405
Net Income Before Taxes -26.64 -33.72 -25.524 -39.624 -41.033
Net Income After Taxes -24.331 -30.795 -22.687 -36.852 -35.303
Net Income Before Extra. Items -24.331 -30.795 -22.687 -36.852 -35.303
Net Income -24.331 -30.795 -22.687 -36.852 -35.303
Income Available to Common Excl. Extra. Items -24.331 -30.795 -22.687 -36.852 -35.303
Income Available to Common Incl. Extra. Items -24.331 -30.795 -22.687 -36.852 -35.303
Diluted Net Income -24.331 -30.795 -22.687 -36.852 -35.303
Diluted Weighted Average Shares 125.356 125.026 124.703 124.425 124.068
Diluted EPS Excluding Extraordinary Items -0.1941 -0.24631 -0.18193 -0.29618 -0.28455
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.17776 -0.21781 -0.16897 -0.26387 -0.26782
Dilution Adjustment
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 605.291 681.508 448.73 290.738 103.668
Cash and Short Term Investments 437.989 515.39 296.259 173.016 9.811
Cash & Equivalents 263.18 316.827 228.713 173.016 9.811
Total Receivables, Net 121.609 113.868 108.486 94.242 76.919
Accounts Receivable - Trade, Net 121.609 113.868 108.486 94.242 76.919
Total Inventory 24.277 23.395 29.526 14.405 8.65
Other Current Assets, Total 6.179 16.501 2.912 2.748 0.561
Total Assets 1740.03 1869.78 988.331 709.506 505.015
Property/Plant/Equipment, Total - Net 198.608 211.662 131.659 90.68 60.888
Property/Plant/Equipment, Total - Gross 330.538 321.614 224.554 159.489 111.015
Accumulated Depreciation, Total -131.93 -109.952 -92.895 -68.809 -50.127
Goodwill, Net 522.766 527.115 211.083 198.601 197.892
Intangibles, Net 408.26 442.325 120.653 126.64 140.029
Other Long Term Assets, Total 5.078 6.932 46.361 2.847 2.538
Total Current Liabilities 89.932 87.232 73.183 63.904 60.925
Accounts Payable 20.51 17.921 24.965 19.568 17.779
Accrued Expenses 61.795 62.984 41.348 32.294 28.048
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.07 1.135 2.841 10.432 14.171
Total Liabilities 742.011 761.501 294.037 202.098 184.572
Total Long Term Debt 535.322 532.554 169.087 95.028 98.13
Long Term Debt 535.322 532.483 168.12 91.829 92.88
Capital Lease Obligations 0.071 0.967 3.199 5.25
Deferred Income Tax 34.75 55.475 5.415 15.566 22.457
Total Equity 998.023 1108.28 694.294 507.408 320.443
Redeemable Preferred Stock 0
Common Stock 0.127 0.124 0.112 0.105 0.094
Additional Paid-In Capital 1160.88 1123.63 701.357 520.278 372.186
Retained Earnings (Accumulated Deficit) -159.087 -14.837 -7.185 -11.357 -51.258
Total Liabilities & Shareholders’ Equity 1740.03 1869.78 988.331 709.506 505.015
Total Common Shares Outstanding 126.914 124.107 112.075 104.781 94.4654
Total Preferred Shares Outstanding 0
Prepaid Expenses 15.237 12.354 11.547 6.327 7.727
Other Current Liabilities, Total 7.557 5.192 4.029 1.61 0.927
Other Liabilities, Total 82.007 86.24 46.352 27.6 3.06
Other Equity, Total -3.899 -0.638 0.01 -1.618 -0.579
Short Term Investments 174.809 198.563 67.546
Long Term Investments 0 29.555
Note Receivable - Long Term 0.031 0.236 0.29
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 586.95 584.72 584.996 605.291 603.36
Cash and Short Term Investments 402.264 409.346 417.915 437.989 443.54
Cash & Equivalents 306.239 289.074 275.609 263.18 266.126
Short Term Investments 96.025 120.272 142.306 174.809 177.414
Total Receivables, Net 133.064 126.235 119.963 121.609 114.673
Accounts Receivable - Trade, Net 133.064 126.235 119.963 121.609 114.673
Total Inventory 24.053 24.945 24.432 24.277 23.799
Prepaid Expenses 18.676 16.571 16.185 15.237 16.511
Other Current Assets, Total 8.893 7.623 6.501 6.179 4.837
Total Assets 1678.24 1695.11 1709.17 1740.03 1755.58
Property/Plant/Equipment, Total - Net 181.648 191.522 196.629 198.608 205.763
Goodwill, Net 522.766 522.766 522.766 522.766 522.766
Intangibles, Net 381.91 390.693 399.477 408.26 416.848
Long Term Investments
Note Receivable - Long Term 0 0 0 0.031 0.257
Other Long Term Assets, Total 4.967 5.407 5.306 5.078 6.588
Total Current Liabilities 92.926 94.848 86.606 89.932 85.003
Accounts Payable 16.819 17.913 22.712 20.51 13.708
Accrued Expenses 72.486 71.212 57.789 61.795 64.791
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.004 0.011 0.038 0.07 0.118
Other Current Liabilities, Total 3.617 5.712 6.067 7.557 6.386
Total Liabilities 730.813 738.916 734.712 742.011 742.594
Total Long Term Debt 537.475 536.755 536.037 535.322 534.609
Long Term Debt 537.475 536.755 536.037 535.322 534.609
Capital Lease Obligations
Deferred Income Tax 25.37 28.811 31.715 34.75 38.345
Other Liabilities, Total 75.042 78.502 80.354 82.007 84.637
Total Equity 947.428 956.192 974.462 998.023 1012.99
Common Stock 0.127 0.127 0.127 0.127 0.127
Additional Paid-In Capital 1181.88 1172.85 1167.05 1160.88 1154.36
Retained Earnings (Accumulated Deficit) -232.729 -214.213 -189.882 -159.087 -136.4
Other Equity, Total -1.846 -2.572 -2.834 -3.899 -5.104
Total Liabilities & Shareholders’ Equity 1678.24 1695.11 1709.17 1740.03 1755.58
Total Common Shares Outstanding 127.261 127.144 127.2 126.914 126.562
Property/Plant/Equipment, Total - Gross 249.357 247.562 241.708 234.429 231.836
Accumulated Depreciation, Total -154.84 -147.452 -138.863 -131.93 -125.018
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -144.25 -8.347 4.172 8.006 2.64
Cash From Operating Activities -65.993 -26.723 1.46 23.369 44.786
Cash From Operating Activities 35.372 30.192 25.904 20.346 15.804
Amortization 34.058 23.16 9.817 9.925 5.928
Non-Cash Items 40.528 -66.737 23.314 17.515 7.901
Cash Taxes Paid 0.18 0.148 0.246 0.319 -0.031
Cash Interest Paid 3.404 3.065 2.926 4.775 6.511
Changes in Working Capital -31.701 -4.991 -61.747 -32.423 12.513
Cash From Investing Activities 0.517 -632.367 -159.441 -19.63 -139.687
Capital Expenditures -30.891 -64.142 -29.096 -20.029 -14.31
Other Investing Cash Flow Items, Total 31.408 -568.225 -130.345 0.399 -125.377
Cash From Financing Activities 11.829 725.285 235.597 159.466 91.959
Financing Cash Flow Items 0 -29.291 -3.317 -1.059 -0.576
Issuance (Retirement) of Stock, Net 12.587 423.213 147.603 171.976 93.998
Issuance (Retirement) of Debt, Net -0.758 331.363 91.311 -11.451 -1.463
Foreign Exchange Effects 0 0 -0.068
Net Change in Cash -53.647 66.195 77.616 163.205 -3.01
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -30.795 -144.25 -121.563 -84.711 -49.408
Cash From Operating Activities -12.692 -65.993 -62.308 -46.036 -29.04
Cash From Operating Activities 9.048 35.372 25.894 16.921 8.395
Amortization 8.783 34.058 25.47 16.979 8.49
Non-Cash Items 8.695 40.528 31.955 21.687 14.54
Cash Taxes Paid 0.18 0.155 0.129 0
Cash Interest Paid 0.432 3.404 2.145 2.143 0.442
Changes in Working Capital -8.423 -31.701 -24.064 -16.912 -11.057
Cash From Investing Activities 23.742 0.517 1.58 5.778 12.052
Capital Expenditures -9.927 -30.891 -26.357 -18.513 -8.219
Other Investing Cash Flow Items, Total 33.669 31.408 27.937 24.291 20.271
Cash From Financing Activities 1.379 11.829 10.027 7.068 6.057
Financing Cash Flow Items 0 0 0 0
Issuance (Retirement) of Stock, Net 1.411 12.587 10.733 7.642 6.403
Issuance (Retirement) of Debt, Net -0.032 -0.758 -0.706 -0.574 -0.346
Net Change in Cash 12.429 -53.647 -50.701 -33.19 -10.931
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
BlackRock Institutional Trust Company, N.A. Investment Advisor 15.0579 19206619 -375594 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 11.4583 14615216 770257 2023-06-30 LOW
Brown Advisory Investment Advisor/Hedge Fund 6.465 8246202 1651717 2023-09-30 LOW
Janus Henderson Investors Investment Advisor/Hedge Fund 5.9501 7589487 165135 2023-06-30 LOW
T. Rowe Price Investment Management, Inc. Investment Advisor 3.9667 5059586 158146 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 3.8623 4926392 40222 2023-06-30 LOW
Emerald Advisers LLC Investment Advisor 2.7322 3484969 453967 2023-09-30 MED
Greenhouse Funds LLLP Hedge Fund 2.5831 3294817 364803 2023-06-30 MED
Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 2.3366 2980374 287767 2023-06-30 LOW
First Light Asset Management, LLC Investment Advisor/Hedge Fund 2.1106 2692057 -6901 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 2.0521 2617439 99568 2023-06-30 LOW
Macquarie Investment Management Investment Advisor 1.7797 2270053 245699 2023-06-30 LOW
Goldman Sachs Asset Management, L.P. Investment Advisor 1.6409 2092984 -114602 2023-06-30 LOW
Schroder Investment Management North America Inc. Investment Advisor 1.5555 1984129 -348305 2023-06-30 LOW
Franklin Advisers, Inc. Investment Advisor/Hedge Fund 1.1286 1439501 71720 2023-06-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.1107 1416714 350417 2022-12-31 LOW
Segall Bryant & Hamill, LLC Investment Advisor/Hedge Fund 1.0514 1341074 220018 2023-06-30 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.9212 1175058 19467 2023-06-30 LOW
Glenmede Investment Management LP Investment Advisor/Hedge Fund 0.8835 1126881 2270 2023-06-30 LOW
Kopp Investment Advisors, LLC Investment Advisor 0.788 1005139 -285880 2023-06-30

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

NeoGenomics Company profile

About NeoGenomics, Inc.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories. The Company operates through two segments: the Clinical Services Segment and the Pharma Services Segment. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research. It offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. It operates testing laboratories in United States, Europe and Asia.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, NeoGenomics, Inc. revenues increased 9% to $484.3M. Net loss totaled $8.3M vs. income of $4.2M. Revenues reflect Clinical Services segment increase of 6% to $404.2M, Pharma Services segment increase of 29% to $80.2M. Net loss reflects General and administrative increase of 38% to $167.2M (expense), Sales and marketing increase of 31% to $62.6M (expense).

Equity composition

Common Stock $0.001 Par, 03/12, 100M auth., 43,236,498. issd. Insiders own approx. 46.49%.

Industry: Medical & Diagnostic Laboratories

9490 Neogenomics Way
FORT MYERS
FLORIDA 33912
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

BTC/USD

51,208.95 Price
-0.920% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Oil - Crude

77.60 Price
-0.790% 1D Chg, %
Long position overnight fee 0.0162%
Short position overnight fee -0.0381%
Overnight fee time 22:00 (UTC)
Spread 0.030

XRP/USD

0.54 Price
-1.930% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Gold

2,022.85 Price
-0.090% 1D Chg, %
Long position overnight fee -0.0185%
Short position overnight fee 0.0103%
Overnight fee time 22:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading